T. Rowe Price Associates
CASC

T. Rowe Price Associates’s Cascadian Therapeutics, Inc. CASC Stock Holding History

T. Rowe Price Associates’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-4,500
Closed -$87K – 2583
2014
Q2 		$87K Hold
4,500
– – ﹤0.01% 2472
2014
Q1 		$81K Buy
4,500
+1,167
+35% +$19.2K ﹤0.01% 2451
2013
Q4 		$35K Buy
+3,333
New +$37.3K ﹤0.01% 2473

Other funds holding CASC

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM

T. Rowe Price Associates's CASC Position: Q3 2014 in Review

T. Rowe Price Associates sold out of Cascadian Therapeutics, Inc. (CASC) in Q3 2014, closing a stake of 4,500 shares — an estimated $87K sold.

T. Rowe Price Associates first reported a position in CASC in Q4 2013 and held it in 3 quarters. The position peaked at $87K in Q2 2014. 86 funds tracked by Wall St. Rank hold CASC as of Q3 2014.

  • T. Rowe Price Associates reported no remaining Cascadian Therapeutics, Inc. position as of Q3 2014 after selling out during the quarter.
  • T. Rowe Price Associates sold 4,500 Cascadian Therapeutics, Inc. shares in Q3 2014, an estimated $87K.
  • T. Rowe Price Associates first reported a position in Cascadian Therapeutics, Inc. in Q4 2013 and held it in 3 quarters.
  • T. Rowe Price Associates's Cascadian Therapeutics, Inc. position peaked at $87K in Q2 2014.
  • 86 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q3 2014.

Based on T. Rowe Price Associates's 13F filing for Q3 2014, filed 14 Nov 2014.